Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 years and up to 3.9 years of treatment: an updated integrated analysis of eight clinical trials

References

• Fridman JS, Scherle PA, Collins R, et al. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J Immunol. 2010;184(9):5298–5307.
   PubMed Web of Science ®Google Scholar
• Guttman-Yassky E, Silverberg JI, Nemoto O, et al. Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study. J Am Acad Dermatol. 2019;80(4):913–921.e9.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Lacour J-P, Spelman L, et al. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol. 2020;183(2):242–255.
   PubMed Web of Science ®Google Scholar
• Reich K, Kabashima K, Peris K, et al. Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(12):1333–1343.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Forman S, Silverberg JI, et al. Baricitinib in patients with moderate-to-severe atopic dermatitis: results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5). J Am Acad Dermatol. 2021;85(1):62–70.
   PubMed Web of Science ®Google Scholar
• Bieber T, Reich K, Paul C, BREEZE-AD4 study group, et al. Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis with inadequate response, intolerance or contraindication to ciclosporin: results from a randomized, placebo-controlled, phase III clinical trial (BREEZE-AD4). Br J Dermatol. 2022;187(3):338–352.
   PubMed Web of Science ®Google Scholar
• Bieber T, Thyssen JP, Reich K, et al. Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials. J Eur Acad Dermatol Venereol. 2021;35(2):476–485.
   PubMed Web of Science ®Google Scholar
• King B, Maari C, Lain E, et al. Extended safety analysis of baricitinib 2 mg in adult patients with atopic dermatitis: an integrated analysis from eight randomized clinical trials. Am J Clin Dermatol. 2021;22(3):395–405.
   PubMed Web of Science ®Google Scholar
• Adas MA, Alveyn E, Cook E, et al. The infection risks of JAK inhibition. Expert Rev Clin Immunol. 2022;18(3):253–261.
   PubMed Web of Science ®Google Scholar
• Fleischmann R. Recent issues in JAK inhibitor safety: perspective for the clinician. Expert Rev Clin Immunol. 2022;18(3):295–307.
   PubMed Web of Science ®Google Scholar
• Ong PY, Leung DY. Bacterial and viral infections in atopic dermatitis: a comprehensive review. Clin Rev Allergy Immunol. 2016;51(3):329–337.
   PubMed Web of Science ®Google Scholar
• Langan SM, Abuabara K, Henrickson SE, et al. Increased risk of cutaneous and systemic infections in atopic dermatitis – a cohort study. J Invest Dermatol. 2017;137(6):1375–1377.
   PubMed Web of Science ®Google Scholar
• Narla S, Silverberg JI. Association between atopic dermatitis and serious cutaneous, multiorgan and systemic infections in US adults. Ann Allergy Asthma Immunol. 2018;120(1):66–72.e11.
   PubMed Web of Science ®Google Scholar
• Droitcourt C, Vittrup I, Kerbrat S, et al. Risk of systemic infections in adults with atopic dermatitis: a nationwide cohort study. J Am Acad Dermatol. 2021;84(2):290–299.
   PubMed Web of Science ®Google Scholar
• Wan J, Shin DB, Syed MN, et al. Risk of herpesvirus, serious and opportunistic infections in atopic dermatitis: a population-based cohort study. Br J Dermatol. 2022;186(4):664–672.
   PubMed Web of Science ®Google Scholar
• Chovatiya R, Silverberg JI. Association of herpes zoster and chronic inflammatory skin disease in US inpatients. J Am Acad Dermatol. 2021;85(6):1437–1445.
   PubMed Web of Science ®Google Scholar
• Seegraber M, Worm M, Werfel T, et al. Recurrent eczema herpeticum—a retrospective european multicenter study evaluating the clinical characteristics of eczema herpeticum cases in atopic dermatitis patients. J Eur Acad Dermatol Venereol. 2020;34(5):1074–1079.
   PubMed Web of Science ®Google Scholar
• Beck LA, Boguniewicz M, Hata T, et al. Phenotype of atopic dermatitis subjects with a history of eczema herpeticum. J Allergy Clin Immunol. 2009;124(2):260–269.
   PubMed Web of Science ®Google Scholar
• Winthrop KL, Harigai M, Genovese MC, et al. Infections in baricitinib clinical trials for patients with active rheumatoid arthritis. Ann Rheum Dis. 2020;79(10):1290–1297.
   PubMed Web of Science ®Google Scholar
• Werfel T, Irvine AD, Bangert C, et al. An integrated analysis of herpes virus infections from eight randomized clinical studies of baricitinib in adults with moderate-to-severe atopic dermatitis. J Eur Acad Dermatol Venereol. 2022;36(9):1486–1496.
   PubMed Web of Science ®Google Scholar
• Thomas K, Vassilopoulos D. Infections in patients with rheumatoid arthritis in the era of targeted synthetic therapies. Mediterr J Rheumatol. 2020;31(Suppl 1):129–136.
   PubMedGoogle Scholar
• Chen JJ, Applebaum DS, Sun GS, et al. Atopic keratoconjunctivitis: a review. J Am Acad Dermatol. 2014;70(3):569–575.
   PubMed Web of Science ®Google Scholar
• Thyssen JP, Toft PB, Halling-Overgaard AS, et al. Incidence, prevalence, and risk of selected ocular disease in adults with atopic dermatitis. J Am Acad Dermatol. 2017;77(2):280–286.e1.
   PubMed Web of Science ®Google Scholar
• Akinlade B, Guttman-Yassky E, de Bruin-Weller M, et al. Conjunctivitis in dupilumab clinical trials. Br J Dermatol. 2019;181(3):459–473.
   PubMed Web of Science ®Google Scholar
• Eichenfield LF, Bieber T, Beck LA, et al. Infections in dupilumab clinical trials in atopic dermatitis: a comprehensive pooled analysis. Am J Clin Dermatol. 2019;20(3):443–456.
   PubMed Web of Science ®Google Scholar
• Andersen YMF, Egeberg A, Gislason GH, et al. Risk of myocardial infarction, ischemic stroke, and cardiovascular death in patients with atopic dermatitis. J Allergy Clin Immunol. 2016;138(1):310–312.e3.
   PubMed Web of Science ®Google Scholar
• Silverwood RJ, Forbes HJ, Abuabara K, et al. Severe and predominantly active atopic eczema in adulthood and long term risk of cardiovascular disease: population based cohort study. BMJ. 2018;361:k1786.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Silverberg JI, Nosbaum A, et al. Integrated safety analysis of abrocitinib for the treatment of moderate-to-severe atopic dermatitis from the phase II and phase III clinical trial program. Am J Clin Dermatol. 2021;22(5):693–707.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency (EMA). Rinvoq assessment report. 2021. https://www.ema.europa.eu/en/documents/variation-report/rinvoq-h-c-004760-x-0006-g-epar-assessment-report-variation_en.pdf.
   Google Scholar
• Bieber T, Feist E, Irvine AD, et al. A review of safety outcomes from clinical trials of baricitinib in rheumatology, dermatology and COVID-19. Adv Ther. 2022;39(11):4910–4960.
   PubMed Web of Science ®Google Scholar
• Meyers KJ, Silverberg JI, Rueda MJ, et al. Risk of venous thromboembolism among patients with atopic dermatitis: a cohort study in a US administrative claims database. Dermatol Ther (Heidelb). 2021;11(3):1041–1052.
   PubMed Web of Science ®Google Scholar
• Legendre L, Barnetche T, Mazereeuw-Hautier J, et al. Risk of lymphoma in patients with atopic dermatitis and the role of topical treatment: a systematic review and meta-analysis. J Am Acad Dermatol. 2015;72(6):992–1002.
   PubMed Web of Science ®Google Scholar
• Brunner PM, Emerson RO, Tipton C, et al. Nonlesional atopic dermatitis skin shares similar T-cell clones with lesional tissues. Allergy. 2017;72(12):2017–2025.
   PubMed Web of Science ®Google Scholar
• Jensen AO, Svaerke C, Kormendine Farkas D, et al. Atopic dermatitis and risk of skin cancer: a danish nationwide cohort study (1977–2006). Am J Clin Dermatol. 2012;13(1):29–36.
   PubMed Web of Science ®Google Scholar
• Gandini S, Stanganelli I, Palli D, et al. Atopic dermatitis, naevi count and skin cancer risk: a meta-analysis. J Dermatol Sci. 2016;84(2):137–143.
   PubMed Web of Science ®Google Scholar
• Arana A, Wentworth CE, Fernández-Vidaurre C, et al. Incidence of cancer in the general population and in patients with or without atopic dermatitis in the U.K. Br J Dermatol. 2010;163(5):1036–1043.
   PubMed Web of Science ®Google Scholar
• Mansfield KE, Schmidt SAJ, Darvalics B, et al. Association between atopic eczema and cancer in England and Denmark. JAMA Dermatol. 2020;156(10):1086–1097.
   PubMed Web of Science ®Google Scholar
• Chahal HS, Rieger KE, Sarin KY. Incidence ratio of basal cell carcinoma to squamous cell carcinoma equalizes with age. J Am Acad Dermatol. 2017;76(2):353–354.
   PubMed Web of Science ®Google Scholar
• Ciążyńska M, Kamińska-Winciorek G, Lange D, et al. The incidence and clinical analysis of non-melanoma skin cancer. Sci Rep. 2021;11(1):4337.
   PubMedGoogle Scholar
• Jiyad Z, Marquart L, Green AC. A call to standardize the BCC: SCC ratio. Br J Dermatol. 2021;184(3):545.
   PubMed Web of Science ®Google Scholar
• Ytterberg SR, Bhatt DL, Mikuls TR, ORAL Surveillance Investigators, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386(4):316–326.
   PubMed Web of Science ®Google Scholar
• Drucker AM, Harvey PJ. Atopic dermatitis and cardiovascular disease: what are the clinical implications? J Allergy Clin Immunol. 2019;143(5):1736–1738.
   PubMed Web of Science ®Google Scholar
• King B, Mostaghimi A, Shimomura T, et al. Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials. Br J Dermatol. 2022; ljac059. DOI:10.1093/bjd/ljac059
   Web of Science ®Google Scholar